Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
2011

EGFR Mutation and Expression in Prostate Cancer

Sample size: 100 publication Evidence: moderate

Author Information

Author(s): Peraldo-Neia Caterina, Migliardi Giorgia, Mello-Grand Maurizia, Montemurro Filippo, Segir Raffaella, Pignochino Ymera, Cavalloni Giuliana, Torchio Bruno, Mosso Luciano, Chiorino Giovanna, Aglietta Massimo

Primary Institution: Department of Clinical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy

Hypothesis

Accurate definition of the EGFR status could improve prognostic stratification and suggest a possible role for EGFR-directed therapies in prostate cancer patients.

Conclusion

EGFR overexpression is significantly associated with biochemical relapse in prostate cancer patients.

Supporting Evidence

  • 36% of tumor samples showed EGFR protein overexpression.
  • 13% of samples had mutations in the EGFR TK domain.
  • Patients with EGFRhigh tumors had a significantly increased risk of biochemical relapse.

Takeaway

This study looked at how a protein called EGFR behaves in prostate cancer. They found that when there's too much of this protein, it can mean the cancer is more likely to come back.

Methodology

EGFR mutation analysis and immunohistochemistry were performed on tumor tissues from 100 prostate cancer patients, with gene expression profiling conducted on 51 samples.

Limitations

The study had a small sample size and was limited to an Italian population, which may affect the generalizability of the results.

Participant Demographics

Patients were of Italian origin, median age 66 years.

Statistical Information

P-Value

0.02

Statistical Significance

p=0.02

Digital Object Identifier (DOI)

10.1186/1471-2407-11-31

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication